Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients

This study has been completed.
Dalhousie University
Information provided by (Responsible Party):
Peter Daley, Christian Medical College Identifier:
First received: August 18, 2006
Last updated: July 4, 2012
Last verified: July 2012

There is some evidence that supplemental Vitamin D may contribute to quicker recovery from TB when given in addition to normal TB therapy. This needs to be proven with a controlled clinical trial. People receiving Vitamin D with anti TB therapy will be compared against people receiving anti TB therapy alone to see if vitamin D contributes to a quicker recovery (as shown by a quicker sputum culture conversion).

Condition Intervention Phase
Pulmonary Tuberculosis
Drug: A. 100,000 IU Cholecalciferol per dose of 3.3ml
Other: B. Migliol Oil without Cholecalciferol
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind, Randomized, Parallel, Placebo Control Design Study to Determine the Effect of Addition of Vitamin D to Conventional Anti TB Therapy

Resource links provided by NLM:

Further study details as provided by Christian Medical College, Vellore, India:

Primary Outcome Measures:
  • Time to sputum culture conversion [ Time Frame: 8 weeks of treatment ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Percent of Patients Culture Positive [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
  • Performance Status [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]
  • Time To Sputum Smear Conversion [ Time Frame: Continous ] [ Designated as safety issue: Yes ]
  • Proportion of Patients Smear Positive [ Time Frame: 4 Weeks, 8 Weeks, 12 Weeks ] [ Designated as safety issue: Yes ]
  • Time To Growth In Liquid Media [ Time Frame: 8 Weeks ] [ Designated as safety issue: No ]
  • RNTCP Treatment Outcomes [ Time Frame: 24 Weeks ] [ Designated as safety issue: Yes ]
  • Weight Gain [ Time Frame: 8 Weeks ] [ Designated as safety issue: Yes ]

Enrollment: 250
Study Start Date: November 2009
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Vitamin D in doses of 100,000 IU
Drug: A. 100,000 IU Cholecalciferol per dose of 3.3ml
100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
Placebo Comparator: B Other: B. Migliol Oil without Cholecalciferol
3.3 ml Migliol Oil, every two weeks for two months

Detailed Description:

The proposed study is a parallel, randomized, double-blinded, placebo-controlled clinical trial to quantify the change, if any, in microbiological outcome in TB patients treated with vitamin D in combination with standard DOTS therapy. It will take place in four South Indian DOTS centres. The required sample size is 250 patients receiving ATT, to be randomised in a 1:1 fashion (125 patients to receive vitamin D and 125 patients to receive placebo).


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Newly diagnosed smear positive pulmonary tuberculosis.
  2. Age between 18 to 75 years
  3. No pre-existing liver or renal disease
  4. Available for return visits as outlined in the trial protocol
  5. A Firm home address

Exclusion Criteria:

  1. Extra-pulmonary or smear negative tuberculosis
  2. Patients receiving steroids, cytotoxic drugs, post transplant or metastatic malignancy, or not expected to survive for the duration of ATT
  3. Pregnant or lactating women
  4. Active diarrhoea, indicating possible fat-soluble vitamin malabsorption.
  5. Baseline Hypercalcemia >10.5 mg/dl
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00366470

Christian Medical College
Vellore, Tamil Nadu, India, 632004
Bethesda Hospital
Ambur, Tamilnadu, India, 635 802
Sponsors and Collaborators
Peter Daley
Dalhousie University
Principal Investigator: Dilip Mathai, MD, FCAMS Christian Medical College, Vellore, India
  More Information

No publications provided

Responsible Party: Peter Daley, Lecturer, Christian Medical College Identifier: NCT00366470     History of Changes
Other Study ID Numbers: TB-VitaminD, CTRI/2007/091/000008
Study First Received: August 18, 2006
Last Updated: July 4, 2012
Health Authority: India: Ministry of Health

Additional relevant MeSH terms:
Tuberculosis, Pulmonary
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Lung Diseases
Mycobacterium Infections
Respiratory Tract Diseases
Respiratory Tract Infections
Vitamin D
Bone Density Conservation Agents
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 24, 2014